Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2003-05-19
2010-10-26
Shukla, Ram R (Department: 1644)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
Reexamination Certificate
active
07820633
ABSTRACT:
A method is disclosed for inducing cell-mediated immunity against cellular antigens. More specifically, the invention provides for a method for inducing cytotoxic T-lymphocyte immunity against weak antigens, notably self-proteins. The method entails that antigen presenting cells are induced to present at least one CTL epitope of the weak antigen and at the same time presenting at least one foreign T-helper lymphocyte epitope. In a preferred embodiment, the antigen is a cancer specific antigen, e.g. PSM, Her2, or FGF8b. The method can be exercised by using traditional polypeptide vaccination, but also by using live attenuated vaccines or nucleic acid vaccination. The invention furthermore provides immunogenic analogues of PSM, Her2 and FGF8b, as well as nucleic acid molecules encoding these analogues. Also vectors and transformed cells are disclosed. The invention also provides for a method for identification of immunogenic analogues of weak or non-immunogenic antigens.
REFERENCES:
patent: 5736142 (1998-04-01), Sette et al.
patent: 7005498 (2006-02-01), Steinaa et al.
patent: 2002/0090379 (2002-07-01), Mouritsen et al.
patent: 2006/0008465 (2006-01-01), Steinaa et al.
patent: 0427347 (1991-05-01), None
patent: WO96/19496 (1996-06-01), None
patent: WO 97/41227 (1997-11-01), None
patent: WO 98/04728 (1998-02-01), None
patent: WO 98/23635 (1998-06-01), None
patent: WO 98/25574 (1998-06-01), None
patent: WO 98/56919 (1998-12-01), None
patent: WO 99/10375 (1999-03-01), None
patent: WO 99/40188 (1999-08-01), None
Fiendly et al. Vaccine Research, 1993, vol. 2, No. 3, 1991, pp. 129-139.
Condon et al. Nature Medicine. 1996, vol. 10, No. 2, pp. 1122-1128.
Renard and Leach (Vaccine, [available online at Science Direct.com], 2007, 25S: B17-B23).
Widmann, C. et al., “T helper epitopes enhance the cytotoxic . . . ,” Journal of Immunological Methods, 155 (1992). pp. 95-99.
Alexander, J. et al., “The optimization of helper t lymphocyte . . . ,” Immunologic Research 1998:18/2. pp. 79-92.
Stoute, J. et al., “A preliminary evaluation of a recombinant . . . ,” The New England Journal of Medicine, 1997, vol. 336 (2).pp. 86-91.
Hanke, T et al., “DNA multi-CTL epitope vaccines . . . ,” Vaccine, 1998, Vol. 16, No. 4, pp. 426-435.
Gilbert, S. et al., A protein particle vaccine containing multiple . . . , Nature Biotechnology, Nov. 1997, vol. 15, pp. 1280.
Marsh, Steven G. E. et al., “Nomenclature for Factors of the HLA System 2002,” Human Immunology, 2002, pp. 1213-1268, vol. 63.
Michalek, Michael T. et al., “A role for the ubiquitin-dependent proteolytic pathway in MHC class I-restricted antigen presentation,” Nautre, Jun. 10, 1993, pp. 552-554, vol. 363.
Donnes, Pierre et al., “Prediction of MHC class I binding peptides, using SVMHC,” BMC Bioinformatics, Sep. 11, 2002, 3:25.
NCBI Database AAA24998—Protein D [gi:148971], 1993.
NCBI Database AAD33252—E6 [Human HPV [gi:148971], 2000.
Dalum, Iben et al., “Induction of cross-reactive antibodies against a self protein by immunizing with a modified self protein containing a foreign T helper Epitope,” Molecular Immunology, 1997, vol. 34, No. 16-17, pp. 1113-1120.
Dalum et al. J. Immunol, vol. 157, 1996, pp. 4796-4804.
Fendly et al. Vaccine Research vol. 2, No. 3, 1991, pp. 129-139.
A—Geneseq—101002 Accession No. AAR06310, Dec. 1990.
A—Geneseq—101002 Accession No. AAW11505, Sep. 1997.
A—Geneseq—101002 Accession No. AAR11896, Jul. 1991.
Molhoj, et al, “Leader sequences are not signal peptides”, Nature Biotechnology, (2004), vol. 22, p. 1502.
Zavala, et al, J Exp Med, (1983), vol. 157, p. 1947-1957.
Steinaa, et al., J Immunology, (2005), vol. 175, pp. 329-334.
Birk Peter
Dalum Iben
Gautam Anand
Haaning Jesper
Karlsson Gunilla
BN Immunotherapeutics, Inc.
Dibrino Marianne
Law Office of Salvatore Arrigo
Shukla Ram R
LandOfFree
Methods for therapeutic vaccination does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for therapeutic vaccination, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for therapeutic vaccination will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4178172